![](/images/byd/115.jpg)
![](/images/byd/149.jpg)
![](/images/byd/269.jpg)
![](/images/byd/67.jpg)
![](/images/byd/227.jpg)
![](/images/byd/359.jpg)
![](/images/byd/84.jpg)
![](/images/byd/122.jpg)
![](/images/byd/268.jpg)
![](/images/byd/101.jpg)
![](/images/byd/141.jpg)
![](/images/byd/355.jpg)
![](/images/byd/92.jpg)
![](/images/byd/153.jpg)
![](/images/byd/347.jpg)
![](/images/byd/5.jpg)
![](/images/byd/236.jpg)
![](/images/byd/276.jpg)
![](/images/byd/75.jpg)
![](/images/byd/131.jpg)
![](/images/byd/334.jpg)
![](/images/byd/27.jpg)
![](/images/byd/197.jpg)
![](/images/byd/241.jpg)
![](/images/byd/69.jpg)
![](/images/byd/188.jpg)
![](/images/byd/253.jpg)
![](/images/byd/116.jpg)
![](/images/byd/174.jpg)
![](/images/byd/348.jpg)
![](/images/byd/118.jpg)
![](/images/byd/190.jpg)
![](/images/byd/256.jpg)
![](/images/byd/32.jpg)
![](/images/byd/238.jpg)
![](/images/byd/252.jpg)
![](/images/byd/73.jpg)
![](/images/byd/147.jpg)
![](/images/byd/350.jpg)
![](/images/byd/57.jpg)
![](/images/byd/208.jpg)
![](/images/byd/256.jpg)
![](/images/byd/14.jpg)
![](/images/byd/232.jpg)
![](/images/byd/340.jpg)
![](/images/byd/112.jpg)
![](/images/byd/127.jpg)
![](/images/byd/322.jpg)
![](/images/byd/86.jpg)
![](/images/byd/182.jpg)
![](/images/byd/328.jpg)
![](/images/byd/31.jpg)
![](/images/byd/201.jpg)
![](/images/byd/302.jpg)
![](/images/byd/78.jpg)
![](/images/byd/125.jpg)
![](/images/byd/242.jpg)
![](/images/byd/98.jpg)
![](/images/byd/139.jpg)
![](/images/byd/287.jpg)
![](/images/byd/22.jpg)
![](/images/byd/184.jpg)
![](/images/byd/269.jpg)
![](/images/byd/45.jpg)
![](/images/byd/158.jpg)
![](/images/byd/320.jpg)
![](/images/byd/36.jpg)
![](/images/byd/225.jpg)
![](/images/byd/249.jpg)
![](/images/byd/105.jpg)
![](/images/byd/182.jpg)
![](/images/byd/318.jpg)
![](/images/byd/77.jpg)
![](/images/byd/187.jpg)
![](/images/byd/283.jpg)
![](/images/byd/101.jpg)
![](/images/byd/146.jpg)
![](/images/byd/347.jpg)
(DOC) НББОУС 2 Бараа материал | Od OD
We assessed the efficacy and safety of the combination of the nucleotide polymerase inhibitor sofosbuvir, the NS5A inhibitor velpatasvir, and the NS3/4A protease inhibitor GS-9857 in patients with hepatitis C virus (HCV) genotype 1 infection. We performed an open-label trial at 32 sites in the United States and 2 sites in New Zealand of 197 ...
![](/image/whatsappp.png)
![](/images/byd/50.jpg)
![](/images/byd/163.jpg)
![](/images/byd/313.jpg)
![](/images/byd/18.jpg)
![](/images/byd/237.jpg)
![](/images/byd/292.jpg)
![](/images/byd/82.jpg)
![](/images/byd/182.jpg)
![](/images/byd/309.jpg)
![](/images/byd/88.jpg)
![](/images/byd/173.jpg)
![](/images/byd/336.jpg)
![](/images/byd/58.jpg)
![](/images/byd/188.jpg)
![](/images/byd/339.jpg)
![](/images/byd/77.jpg)
![](/images/byd/137.jpg)
![](/images/byd/267.jpg)
![](/images/byd/41.jpg)
![](/images/byd/219.jpg)
![](/images/byd/253.jpg)
![](/images/byd/114.jpg)
![](/images/byd/193.jpg)
![](/images/byd/338.jpg)
![](/images/byd/72.jpg)
![](/images/byd/194.jpg)
![](/images/byd/285.jpg)
![](/images/byd/112.jpg)
![](/images/byd/179.jpg)
![](/images/byd/311.jpg)
![](/images/byd/106.jpg)
![](/images/byd/135.jpg)
![](/images/byd/242.jpg)